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Available online 2 March 2016Objective: The objectives of these two studies were to determine if beads from extended-release topiramate cap-
sules sprinkled onto soft food are bioequivalent to the intact capsule and if beads from the capsule can be passed
through enteral gastrostomy (G-) and jejunostomy (J-) feeding tubes.
Methods: Bioequivalence of 200-mg USL255 (Qudexy® XR [topiramate] extended-release capsules) sprinkled
onto soft food (applesauce) versus the intact capsule was evaluated in a phase 1, randomized, single-dose, cross-
over study (N= 36). Pharmacokinetic evaluations included area under the curve (AUC), maximum plasma con-
centration (Cmax), time to Cmax (Tmax), and terminal elimination half-life (t1/2). If 90% conﬁdence intervals (CI) of
the ratio of geometric least-squaresmeanswere between0.80 and 1.25, AUC andCmaxwere considered bioequiv-
alent. In separate in vitro experiments, 100-mg USL255 beads were passed through feeding tubes using gentle
syringe pressure to develop a clog-free bead-delivery method. Multiple tube sizes (14- to 18-French
[Fr] tubes), dilutions (5 mg/15 mL–25 mg/15 mL), and diluents (deionized water, apple juice, Ketocal, sparkling
water) were tested.
Results: Area under the curve and Cmax for USL255 beads sprinkled onto applesaucewere bioequivalent to the in-
tact capsule (GLSM [90% CI]: AUC0–t 1.01 [0.97–1.04], AUC0–∞ 1.02 [0.98–1.05]; Cmax 1.09 [1.03–1.14]). Median
Tmax was 4 h earlier for USL255 sprinkled versus the intact capsule (10 vs 14 h; p= 0.0018), and t1/2 was similar
(84 vs 82 h, respectively). In 14-Fr G-tubes, USL255 beads diluted in Ketocal minimized bead clogging versus de-
ionized water. Recovery of USL255 beads diluted in deionized water was nearly 100% in 16-Fr G-, 18-Fr G-, and
18-Fr J-tubes.
Signiﬁcance: For patients with difﬁculty swallowing pills, USL255 sprinkled onto applesauce offers a useful once-
daily option for taking topiramate. USL255 beads were also successfully delivered in vitro through ≥14-Fr G- or J-
tubes, with tube clogging minimized by portioning the dose and using glidant diluents for smaller tubes.
© 2016 Upsher-mith Laboratories, Inc. Published by Elsevier Inc. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Sprinkle1. Introduction
The recent inﬂux of new antiepileptic drugs (AEDs) has provided ad-
ditional options for seizure management [1]; however, the majority of
AEDs are often formulated as capsules or tablets [2], which may not be
suitable treatment options for all patients with epilepsy. The incidence
of epilepsy is high in pediatric and elderly patients,whooften have trou-
ble swallowing medications [3,4]. Additionally, patients with epilepsy
may suffer from dysphagia as a result of medical conditions that com-
monly coexist with epilepsy—such as cerebral palsy and intellectual/
physical disabilities [5,6]. Regardless of their cause, swallowingple Grove, MN 55369, United
Clark).
nc. Published by Elsevier Inc
).difﬁculties in these patients with epilepsy can contribute to suboptimal
drug adherence [6].
Newer AEDs, including extended-release (XR) drugs with less fre-
quent dosing and sprinkle formulations, may provide an improved
treatment option for patients with swallowing difﬁculties, which in
turn, may increase medication adherence and seizure control. Newer
formulations and alternate delivery options also are needed for the
subpopulation of patients with epilepsy in which feeding tubes are
surgically implanted [7] due to swallowing difﬁculties secondary to
neurological comorbidities [8].
USL255, Qudexy® XR (topiramate) extended-release capsules
(Upsher-Smith Laboratories, Maple Grove, MN, U.S.A.), is a once-daily,
XR formulation of topiramate—a broad-spectrum, well-established
AED—available as 25-mg, 50-mg, 100-mg, 150-mg, and 200-mg cap-
sules. In previous phase 1 studies, USL255 displayed dose proportional. This is an open access article under the CC BY-NC-ND license
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topiramate dosed twice daily, provided equivalent topiramate exposure
with a 26% decreased ﬂuctuation index at steady state [10]. A placebo-
controlled, randomized, multinational phase 3 study found that
USL255 200 mg was efﬁcacious and generally well tolerated in the
adjunctive treatment of partial-onset seizures (POS) [11,12]. USL255 is
approved in the United States in patients ≥2 years of age as monother-
apy for POS or primary generalized tonic-clonic (PGTC) seizures, and
adjunctive therapy for POS, PGTC seizures, or seizures associated with
Lennox-Gastaut syndrome [13].
USL255 is a proprietarymultiparticulate (beads in a capsule) formu-
lation that can be swallowed whole or opened and sprinkled onto soft
food, which may provide a once-daily alternative for those patients
experiencing swallowing difﬁculties. The purpose of this publication is
to present ﬁndings from two separate studies that evaluated the clinical
utility of USL255 delivery methods. In the ﬁrst investigation, the bio-
equivalence of USL255 beads sprinkled onto soft food (applesauce) ver-
sus the intact capsule was assessed in a phase 1 study in healthy adults.
In the second study, exploratory in vitro experiments were performed
to assess the delivery of various dilutions of USL255 beads in multiple
diluents passed through enteral gastrostomy (G-tube) and jejunostomy
(J-tube) feeding tubes.
2. Methods
2.1. Bioequivalence of USL255 beads sprinkled onto applesauce versus the
intact capsule postovernight fast
2.1.1. Study overview
A phase 1 study in healthy adults was used to assess the bioequiva-
lence of USL255 beads sprinkled onto applesauce (herein referred to as
“sprinkled”) compared with the intact capsule. This studywas conduct-
ed in accordance with the International Conference on Harmonisation
(ICH) E6, Guideline for Good Clinical Practice (GCP), and all applicable
regulatory requirements. The study protocol was reviewed and ap-
proved by the IntegReview Institutional Review Board. Prior to random-
ization, all participants provided written informed consent.
2.1.2. Study design
This was a phase 1, randomized, single-center, open-label, single-
dose, 4-way crossover study in which 36 healthy adults were enrolled
into 1 of 4 treatment sequences (n = 9/sequence), each with 4 treat-
ment periods (21-day minimum washout between treatments).
Treatment periods included a single dose of an entire USL255 200-mg
capsule sprinkled onto 1 tablespoonful of applesauce after an overnight
fast and a single dose of a USL255 200-mg capsule administered intact
after an overnight fast. The PK data from two additional USL255-
treatment periods do not pertain to the primary objectives of this
publication and are, therefore, not included here. Participants were con-
ﬁned to the clinic for at least 36 h pretreatment and 48 h posttreatment.
2.1.3. Study participants
Participants in the phase 1 study were healthy men and women
between 18 and 65 years of age, who had a body mass index (BMI)
between 18 and 30 kg/m2 and weighed at least 110 lb. Participants
were required to have abstained from consuming alcohol-, caffeine-,
and xanthine-containing beverages for 36 h before and 72 h after each
dose, and refrained from the use of tobacco products within 90 days be-
fore screening and until the ﬁnal study visit. Participants with a known
hypersensitivity to topiramate or any excipient in USL255 aswell as hy-
persensitivity to apples, applesauce, or its constituents were excluded
from the study. Additional key exclusion criteria included: a clinically
relevant current illness (within 4 weeks before dosing) or clinical histo-
ry that would interfere with the participant's ability to complete the
study or confound the results of this study (as determined by the inves-
tigator); a predisposing condition that could interfere with theabsorption, distribution,metabolism, or excretion of drugs; prescription
medication taken within 14 days before the initial PK study period or
taken over-the-counter oral preparations, including dietary and herbal
supplements, within 3 days before the initial PK study period; or a his-
tory of clinically signiﬁcant alcohol or drug abuse.
Participant demographics, baseline characteristics, and safety/
tolerability analyses were based on the safety population, deﬁned as
all randomized participants who received at least 1 dose of study
drug. The PK population was deﬁned as all participants who received
at least 1 dose of any treatment and for whom sufﬁcient PK samples
were collected for accurate estimation of PK parameters. The bioequiv-
alence population was a subset of the PK population and included all
participants who completed the treatment periods being compared
(i.e., USL255 beads sprinkled vs intact USL255 capsule).
2.1.4. Pharmacokinetic and safety/tolerability analyses
Blood samples were drawn within 1 h predose (0 h), every 2 h until
32 h postdose, and at 36, 48, 72, 96, 120, 168, 216, 264, and 336 h
postdose. The PK samples were analyzed for topiramate using high per-
formance liquid chromatography with tandem mass spectrometry
(HPLC MS/MS), with a lower limit of quantiﬁcation of 10 ng/mL as pre-
viously described [14]. Standard PK parameters were calculated from
the plasma concentration–time data using noncompartmentalmethods
[15] and included area under the plasma concentration–time curve
from time zero to time of last quantiﬁable concentration (AUC0–t) calcu-
lated by linear trapezoidal rule, AUC from time zero to inﬁnity (AUC0–∞),
maximum plasma concentration (Cmax), time to Cmax (Tmax), and termi-
nal elimination half-life (t1/2).
Safety and tolerability assessments were conducted at baseline and
throughout the study. Treatment-emergent adverse events (TEAEs) re-
ported during the study were categorized by the investigator based on
intensity (mild, moderate, severe) and relationship to study drug.
Additional evaluations included vital signs, electrocardiogram (ECG)
ﬁndings, physical examination, and clinical laboratory evaluations
(e.g., hematology, serum chemistry, and urinalysis). Suicidality assess-
ment via the Columbia—Suicide Severity Rating Scale (C-SSRS) also
was performed at each study check-in, check-out, and ﬁnal study visit.
2.1.5. Statistical analyses
Bioequivalence for AUC and Cmax was established if the 90% conﬁ-
dence intervals (CI) for the ratio of geometric least-squares means
(GLSM) were contained within the 0.80–1.25 equivalence limits. This
methodology is in line with guidance from the US Federal Drug
Administration regarding bioequivalence studies. Wilcoxon signed-
rank test was used for nonparametric comparison of Tmax values.
Descriptive statistics were calculated for the safety and tolerability
assessments.
2.2. In vitro delivery of USL255 beads via enteral feeding tubes
2.2.1. Study overview
USL255 beads cannot be crushed into a powder or modiﬁed prior to
dosing, as this may compromise the extended-release characteristics of
the drug. Therefore, exploratory in vitro experiments were performed
to assess delivery methods to minimize clogging of feeding tubes with
intact beads. To determine the optimal method, various dilutions of
USL255 beads in multiple diluents were passed through G- and
J-tubes using gentle syringe pressure. Tube sizes included 14, 16, and
18 Mic™ French unit (Fr) G-tubes (~25 cm in length) and 18-Fr J-tube
(~75 cm in length), where 1 Fr is equal to 0.33 mm. Large-bore
(≥14 Fr) feeding tubes are preferred for delivering medications [7],
and the 14- to 18-Fr G-tubes and 18-Fr J-tubes assessed in these exper-
iments are commonly used in pediatric and adult patients.
A number of diluents for bead delivery were evaluated. Deionized
water was evaluated in all tube sizes (14, 16, and 18 Fr). Ketocal®
(Nutricia, Gaithersburg, MD, U.S.A.), apple juice, and sparkling water
Table 2
Participant disposition and demographics (safety population).
Overall study participants
N = 36
Randomized, n (%) 36 (100)
Completed, n (%) 29 (80.6)a
Discontinued, n (%) 7 (19.4)b
Age, mean (range), years 41.3 (18–64)
Male, n (%) 20 (55.6)
Race, n (%)
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chances of tube clogging; theses diluents were selected based upon
their potential glidant properties, as well as recommendations from
external clinicians regarding what diluents are often used with
patients in their clinical practice. Ketocal is a nutritionally dense
formula used to administer the classic ketogenic diet (4:1 ratio of
fat:carbohydrate + protein) for dietary management of intractable ep-
ilepsy [8]. The dilution scheme for feeding tube experiments is summa-
rized in Table 1.White 29 (80.6)
African American 4 (11.1)
American Indian or Alaska native 3 (8.3)
a Includes participantswho completed all 4 USL255 treatment arms; 2 of those treatment
arms (USL255 sprinkled and USL255 intact) are detailed in this publication (see Methods
section).
b A total of 7 participants discontinued early due to protocol noncompliance (n = 4),
lost to follow-up (n = 2), and personal reasons (n = 1).2.2.2. Study design
The overall experimental method was as follows. First, the G- and J-
tubes were ﬂushed with 15-mL deionized water prior to USL255 bead
delivery. The number of beads per 100-mg USL255 (four 25-mg cap-
sules) were counted and recorded. The total dose of USL255 was divid-
ed, and each portion was suspended in 15 mL of diluent in a small
beaker. While using a swirling motion, suspended beads were gently
pushed through a primed, appropriately sized irrigation syringe at-
tached to the medication port of the feeding tube. For all G-tube exper-
iments, 60-mL irrigation syringes were used while a 35-mL irrigation
syringe was used for the 18-Fr J-tube experiment. The process of deliv-
ering each bead portion via gentle pressure method was repeated until
all bead portions from the total dose were delivered. Next, the beaker
was rinsed with 10-mL portions of diluent (15-mL portions were used
for sparkling water experiments) and poured into the syringe until no
beads remained in the beaker; the total volumeusedwas then recorded.
Following rinsing of the beaker, the number of beads remaining in the
syringe and tube were recorded. Finally, the tube was then ﬂushed
with an additional 15-mL diluent and the number of beads in the sy-
ringe and tube after ﬂushing was recorded.2.2.3. Data analyses
Experimental procedures were performed in triplicate and accep-
tance criteria was deﬁned as percent recovery of no less than 98% of
beads transferred for each replicate (Eq. (1)).
Percent recovery ¼ 100 n0−nfð Þ=n0
n0 ¼ initial number of beads
nf ¼ number of beads observed on tubing=syringe
ð1ÞTable 1
USL255 dilution scheme for enteral feeding tube delivery.
Deionized
water
Ketocala,b Apple
juiceb
Sparkling
waterb
14-Fr G-tube 5 mg/15 mL X X
10 mg/15 mL Xc X X
20 mg/15 mL Xc X X
25 mg/15 mL Xc
16-Fr G-tube 12.5 mg/15 mL X X X
25 mg/15 mL X X X
18-Fr G- or
J-tube
25 mg/15 mL X X X
A total dose of 100-mg USL255 was used for all experiments.
indicates dilution was tested; X indicates dilution was not tested.
Fr refers to ‘French units’ where 1 Fr = 0.33 mm.
a Ketocal is a nutritionally dense formula that can be used to administer the classical
ketogenic diet (4:1 ratio of fat:carbohydrate + protein) for dietary management of
intractable epilepsy.
b Diluents with potential glidant properties were used to assess if they may lessen the
chances of tube clogging.
c Due to clogging at the lowest dilution (5 mg/15 mL), more concentrated dilutions
were not tested.3. Results
3.1. Bioequivalence of USL255 beads sprinkled onto applesauce versus the
intact capsule postovernight fast
3.1.1. Participant disposition, demographics, and baseline characteristics
A total of 36 healthy adults were randomized to 1 of 4 treatment se-
quences. Their demographics are presented in Table 2.
Of the 36 randomized study participants, 29 (80.6%) completed the
entire 4-arm study, including 2 additional treatment periods not de-
scribed here (Table 2). A total of 33 participants received USL255
200 mg sprinkled or administered intact (i.e., safety population) and
had sufﬁcient samples for accurate estimation of PK parameters (i.e.,
PK population). Bioequivalence of treatments was assessed in all of
the 31 participants who received single doses of both USL255 sprinkled
and intact (i.e., bioequivalence population).
3.1.2. Plasma topiramate concentrations
Mean plasma concentration–time proﬁles were similar following a
single dose of USL255 200 mg sprinkled or administered intact for the
participants with sufﬁcient samples for PK estimates (Fig. 1).
Pharmacokinetic evaluations of USL255 demonstrated that the
mean AUC, Cmax, and t1/2 values were similar when USL255 was sprin-
kled or the capsule was administered intact (Table 3). Median Tmax
was 4 h earlier for USL255 sprinkled compared with that for the intactFig. 1. Mean topiramate plasma concentrations following single-dose USL255
administration (PK population). Depicted are the plasma concentration–time proﬁles for
USL255 200 mg sprinkled onto applesauce or administered as an intact capsule, both
administered following an overnight fast for participants in the PK population (n = 33
each). The inset shows the complete 0- to 336-hour curve.
Table 3
PKparameters and bioequivalence ofUSL255 sprinkled onto soft food and administered as
an intact capsule (PK and bioequivalence populations).
USL255 200 mg
sprinkled
(n = 33)
USL255 200 mg
intact
(n = 33)
AUC0–t, μg·hr/mL Mean (SD) 188 (33) 188 (34)
GLSM 195a 194a
GLSM ratio (90% CI) 1.01 (0.97–1.04)a
AUC0–∞, μg·hr/mL Mean (SD) 193 (34)b 192 (35)b
GLSM 200c 197c
GLSM ratio (90% CI) 1.02 (0.98–1.05)c
Cmax, μg/mL Mean (SD) 3.4 (0.61) 3.2 (0.70)
GLSM 3.6a 3.3a
GLSM ratio (90% CI) 1.09 (1.03–1.14)a
Tmax, hours Median 10d 14d
t1/2, hours Mean (SD) 84 (17)b 82 (22)b
Bioequivalence for AUC and Cmax was established if the 90% CI for GLSM ratio of
sprinkled:intact were contained between 0.80 and 1.25.
AUC0–t, area under the plasma concentration–time curve from time 0 to last measurable
time point; AUC0–∞, area under the plasma concentration–time curve from time 0 to inﬁn-
ity; CI, conﬁdence interval; Cmax, maximumplasma concentration; GLSM, geometric least-
squares mean; SD, standard deviation; t1/2, terminal elimination half-life; Tmax, time to
maximum plasma concentration.
a n = 31 (bioequivalence population).
b n = 32.
c n = 29.
d Wilcoxon signed-rank test was used for nonparametric comparison of Tmax values
(p = 0.0018).
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for AUC and Cmax werewithin the 0.80–1.25 equivalence limits, demon-
strating that USL255 sprinkled onto applesauce was bioequivalent to
the intact capsule (Table 3).
3.2. Safety and tolerability of USL255
USL255 was generally well tolerated, with similar TEAEs reported
after administration of USL255 200-mg capsule sprinkled or adminis-
tered intact (Table 4). All TEAEs were either mild or moderate in inten-
sity, andmostwere deemed related to treatment. Of the TEAEs observed
in ≥5% of participants in either treatment group, nausea, paresthesia,Table 4
Summary of TEAEs reported during the study for either treatment (safety population).
n (%) USL255 200 mg
sprinkled
(n = 33)
USL255 200 mg
intact
(n = 33)
Participants with ≥1 TEAE 16 (48.5) 16 (48.5)
Participants with ≥1 treatment-related AEa 14 (42.4) 12 (36.4)
Participants with ≥1 SAE 0 0
Intensity of TEAEs
Mild 14 (42.4) 15 (45.5)
Moderate 9 (27.3) 8 (24.2)
Severe 0 0
TEAEs with an incidence of ≥5% for either treatmentb
Paresthesia 5 (15.2) 3 (9.1)
Headache 5 (15.2) 2 (6.1)
Nausea 4 (12.1) 4 (12.1)
Dizziness 3 (9.1) 4 (12.1)
Constipation 2 (6.1) 2 (6.1)
Diarrhea 2 (6.1) 1 (3)
Anorexia 2 (6.1) 0
Insomnia 2 (6.1) 0
Dysgeusia 1 (3) 2 (6.1)
Reported here are adverse events that commenced within 21 days following study drug
administration.
AE, adverse event; SAE, serious adverse event; TEAE, treatment-emergent adverse event.
a Adverse events with causality of possibly, probably, deﬁnitely, or unknown were
considered treatment related.
b Listed in descending order of frequency for TEAEs reported with administration of
USL255 sprinkled onto soft food.dizziness, and headache were the most commonly reported (Table 4).
There were no deaths or TEAEs that led to study discontinuation.
Other than the single event of hypotension, there were no clinically
important ﬁndings on vital sign, ECG, or physical examination assess-
ments. Overall, mean hematology and serum chemistry parameters
were within reference ranges, and no differences were observed be-
tween the two treatment periods. No participants had clinically mean-
ingful changes in C-SSRS evaluations during the study.
3.3. In vitro delivery of USL255 beads via enteral feeding tubes
3.3.1. 14-Fr G-tubes: bead recovery and dosing volume using multiple
diluents
A 100-mg dose of USL255 diluted in deionizedwater clogged the 14-
Fr G-tube, even at the lowest concentration (5-mg topiramate/15-mL
deionized water); as such, more concentrated dilutionswere not evalu-
ated. Diluting USL255 beads in apple juice at the highest concentration
of 25 mg/15 mL was generally successful, with an average of 99.7%
bead recovery in 113-mL dosing volume. In 1 replicate with apple
juice, the 14-Fr G-tube clogged during the ﬁnal beaker wash but was
easily dislodged. USL255 beads diluted at 25 mg/15 mL in sparkling
water resulted in 100% bead recovery in 220-mL dosing volume, though
a small fraction of beads in each dose stuck to the beaker or ﬂoated in
the diluent due to carbonation, making it difﬁcult to transfer to the sy-
ringe. USL255 bead recovery with Ketocal was successful for all dilution
schemes with no tube clogging in 14-Fr G-tubes (Table 5).
3.3.2. 16 and 18-Fr G-tubes and 18-Fr J-tubes: bead recovery and dosing
volume using deionized water
Recovery of USL255 100 mg in 25-mg/15-mL portions, with deion-
ized water as the diluent, resulted in clogging the 16-Fr G-tube. In
these tubes, bead recovery was successful at half the concentration
(12.5 mg/15 mL; Table 5). Diluting USL255 100 mg with deionized
water in 25-mg/15-mL portions was successful for the 18-Fr G-tube
and 18-Fr J-tube, with bead recovery at or above 99.6% and dosing
volume ranging from 100 to 120 mL for all doses and concentrations
evaluated (Table 5).
4. Discussion
The purpose of this publication was to provide additional informa-
tion on the clinical utility of USL255, particularly for individuals with
swallowing difﬁculties. The two studies presented here focused on dif-
ferent properties of the USL255 capsule. In the ﬁrst, the bioequivalence
of USL255 sprinkled and administered intact was evaluated in healthy
participants. In the second study, varying conditions to pass USL255
beads through enteral feeding tubes in order to minimize bead clogging
were assessed in vitro, including multiple diluents, bead dilutions, and
tube sizes. Together, these studies provide information that can be
used by clinicians when treating patients of all ages with swallowing
difﬁculties.
4.1. Bioequivalence of USL255 beads sprinkled onto applesauce versus the
intact capsule postovernight fast
In the phase 1 study in healthy adults presented here, USL255 sprin-
kled demonstrated bioequivalence with the intact capsule for both AUC
and Cmax and similar t1/2, indicating that the two administration
methods provide similar topiramate exposure. The plasma concentra-
tion–time proﬁle also indicated that sprinkling did not impact the XR
properties of USL255.
Median Tmaxwas earlier for USL255 sprinkled (10 h) comparedwith
that for the intact capsule (14 h); however, this is not entirely unexpect-
ed, as ingestion of the beadswithout the capsule shell may lead to faster
absorption. This is supported by a PK study of XR morphine, in which
mean Tmax was ~4.5 h faster with the sprinkle dose versus the intact
Table 5
Bead recovery and dosing volumes following USL255 bead delivery via enteral feeding tubes.
Tube size Diluent Dilution Replicate 1 Replicate 2 Replicate 3
14-Fr G-tube Ketocal 5 mg/15 mL Bead recovery,a % 100 100 99.7
Dosing volume,b mL 340 340 340
10 mg/15 mL Bead recovery,a % 99.4 99.9 100
Dosing volume,b mL 190 210 200
20 mg/15 mL Bead recovery,a % 100 100 99.9
Dosing volume,b mL 135 125 135
25 mg/15 mL Bead recovery,a % 100 99.9 99.9
Dosing volume,b mL 110 110 110
Apple juice 25 mg/15 mL Bead recovery,a % 99.7 99.6 99.8
Dosing volume,b mL 110 110 120
Sparkling water 25 mg/15 mL Bead recovery,a % 100 100 100
Dosing volume,b mL 220 220 220
Deionized water 5 mg/15 mL Bead recovery,a % 97.8 b98c NA
Dosing volume,b mL 340 NA NA
16-Fr G-tube Deionized water 12.5 mg/15 mL Bead recovery,a % 100 100 100
Dosing volume,b mL 160 170 180
25 mg/15 mL Bead recovery,a % b98c NA NA
Dosing volume,b mL NA NA NA
18-Fr G-tube Deionized water 25 mg/15 mL Bead recovery,a % 99.6 100 99.8
Dosing volume,b mL 120 120 120
18-Fr J-tube Deionized water 25 mg/15 mL Bead recovery,a % 99.8 100 100
Dosing volume,b mL 110 110 100
A 100-mg total dose was used for all experiments.
Dosing indicates mg topiramate/mL diluent.
NA (not applicable) indicates that the experiment was not repeated due to clogging of the ﬁrst replicate.
a Bead recovery calculated after postﬂush washout of syringe.
b Dosing volume includes 15-mL deionized water used to preﬂush the feeding tube and 15-mL diluent used postﬂush.
c Less than 98%, tube clogging observed.
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important to note, however, that the statistically signiﬁcant difference
in USL255 Tmax is not expected to be clinically signiﬁcant, as there was
no effect on the bioequivalence of Cmax or AUC. Additionally, slight dif-
ferences in Tmax would not be expected to impact the overall efﬁcacy
of a once-daily drug used chronically for the treatment of epilepsy.
Similar TEAEswere reported after administration of USL255 200-mg
capsule sprinkled or administered intact. The most common TEAEs in
either treatment group were nausea, paresthesia, dizziness, and head-
ache, and all TEAEs were mild or moderate in intensity. These adverse
events were not unexpected for topiramate and have been observed
in previous studies of USL255, both in healthy participants and in
patients with epilepsy [9–11,14,17].
The ability to sprinkle the beads contained within the USL255 cap-
sule may be particularly useful for children or elderly patients who
tend to have a high incidence of epilepsy and swallowing difﬁculties
[3,4]. Children often have difﬁculties swallowing capsules or tablets
until 6 years of age, and approximately 15% of elderly patients
experience dysphagia [18], which can result from aging as well as the
effects of concomitant medications or comorbid medical conditions
(e.g., stroke) [5,6]. While many immediate-release AEDs offer drug
formulations that may be well suited for patients with swallowing
difﬁculties (e.g., oral suspensions or sprinkle capsules), only 3 XR
AEDs—carbamazepine, divalproex sodium, and USL255—have been de-
veloped in a sprinkle formulation [17]. These may be the most optimal
for patients with swallowing difﬁculties, as XR formulations offer the
convenience of reduced dosing frequency and pill burden with the ad-
vantage of a sprinkle administration route. Of the currently available
topiramate formulations, USL255 is the only XR topiramate sprinkle
formulation. Additionally, it is the only XR topiramate approved for
monotherapy or adjunctive treatment of POS, PGTC seizures, and/or
Lennox–Gastaut syndrome in children ≥2 years of age, which includes
the age range of children who may not be able to swallow tablets/cap-
sules. Thus, the option to sprinkle USL255 beads onto soft food provides
a potential alternative for a variety of patients with epilepsy who have
difﬁculties swallowing.
A limitation of this single-dose study is that the bioequivalence data
were obtained from healthy adults and not in patients with epilepsy,whichmay exhibit differences in drug absorption, distribution,metabo-
lism, and excretion. Additionally, as this study evaluated PK following a
single-dose of USL255, the impact of sprinkle on AUC, Cmax, and Tmax
following steady-state administration has not be evaluated. However,
single-dose studies are generally recommended by the US FDA to assess
bioequivalence because they tend to be more sensitive than steady-
state studies.
4.2. Delivery of USL255 beads via enteral feeding tubes
Optimized treatment options are also important for the subpopula-
tion of patients with epilepsy in which feeding tubes may be surgically
implanted [7] due to swallowing difﬁculties secondary to neurological
comorbidities [8]. Patients who require feeding tubes may also beneﬁt
from treatment with XR AEDs that reduce the number of times per
day that medication is passed through the feeding tube, which may
aid caregivers and patients alike.
The in vitro experiments reportedhere showed that USL255bead re-
covery was nearly 100% in ≥14-Fr G-tubes and 18-Fr J-tubes evaluated,
and tube clogging was prevented by portioning the dose and using a
glidant diluent for smaller diameter tubes. These exploratory in vitro
analyses provide the ﬁrst insight into the potential for USL255 bead
delivery via enteral feeding tubes.
A limitation of these evaluations is that they were not performed in
patients with feeding tubes. Maintenance of seizure control, the safety
proﬁle, and optimal procedure for delivering USL255 beads through
feeding tubes have yet to be determined in patientswith epilepsy. Over-
all, there are limited publications evaluating the delivery of AED sprin-
kle formulations via feeding tubes. In a 1992 study, Jones-Saete et al.
administered valproate sprinkle (VPA-S) to 8 patients (7 children,
1 adult) with feeding tubes of either the standard Foley “mushroom”
or “button” type [19]. Delivery of a VPA-S “slurry” in 1 oz of formula
was allowed to run in by gravity, and was then ﬂushed with remaining
formula. Within weeks to months after therapy with VPA-S, 4 of the
8 patients had leakage, which was controlled in 3 patients by re-
placement of the tube and/or use of a larger catheter. The authors hy-
pothesized that the higher incidence of leakage with VPA-S was
caused by deposition of undissolved particles on the surface of the
110 A.M. Clark et al. / Epilepsy & Behavior 57 (2016) 105–110exterior tube, but noted that leaking complications in patients areminor
and usually manageable [19].
Though alternative methods of bead delivery were not evaluated in
the VPA-S study, in 2002, Riss et al. assessed the delivery of XR carba-
mazepine via enteral feeding tubes in a set of in vitro experiments and
a small clinical study (N = 6, patients 6–20 years of age) [20]. When
testing different diluents (deionized water, apple juice, or a nutritional
supplement) and connectors (straight or angled) in 14- to 24-Fr
G-tubes during the in vitro experiments, Riss et al. reported that clog-
ging was most likely to occur when using right-angled enteral feeding
tubes (not tested in our study), and when using deionized water or
apple juice versus the nutritional supplement [20]. During the clinical
study, 4 of the 6 patients were successfully given XR carbamazepine
via feeding tubes with little occlusion. The dosing volumes used in
their in vitro experimentsweremuch smaller than those used in the ex-
periments for USL255, which may explain the increased clogging they
observed. Moreover, Riss et al. did not evaluate portioning the dose, as
was done here, which may be particularly important for minimizing
clogging during feeding tube delivery of AEDs [20].
5. Conclusions
A single dose of a USL255 200-mg capsule sprinkled onto applesauce
was generally safe andwell tolerated, anddemonstrated bioequivalence
to the intact capsule. In vitro delivery of USL255 beads via enteral feed-
ing tubes was examined as an alternative delivery route in large-bore
(≥14 Fr) feeding tubes commonly used in pediatric and adult patients.
Using a diluent with glidant properties (e.g., Ketocal, apple juice, spar-
kling water), essentially 100% of beads passed through 14-Fr G-tubes;
deionized water and portioning of dose resulted in 100% bead delivery
in 16-Fr G-tubes and 18-Fr G- and J-tubes. The multiparticulate formu-
lation of USL255, Qudexy® XR (topiramate) extended-release capsules,
offers an important alternative for those patients whomay be unable to
swallow intact capsules.
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